AstraZeneca (AZN) Stock
NYSE · AZN
166.51
Fundamentals
Market cap
$257.67B
Price / Earnings ratio
24.2x
Price / Sales ratio
4.1x
Price / Book ratio
5.0x
Return on assets
0.1%
Ex-Dividend date
7 Aug 2026
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
1.9%
Debt / Equity ratio
N/A
Latest news
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide
SectorHealthcare
IndustryDrug Manufacturers - General
Employees96,100
CEOMr. Pascal Claude Roland Soriot D.V.M., M.B.A.
IPO DateMay 17, 1993
HeadquartersCambridge, United Kingdom
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Pascal Claude Roland Soriot D.V.M., M.B.A. | CEO & Executive Director | 1959 |
| Dr. Aradhana Sarin M.D. | CFO & Executive Director | 1974 |
| Ms. Pam P. Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board | 1970 |
| Mr. Joris Silon | Head of Investor Relations | — |
| Mr. Jeffrey Pott J.D. | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board | — |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit | — |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology R&D | 1966 |
| Ms. Iskra Reic | Executive Vice President of International | — |
| Mr. David Fredrickson | Executive Vice-President of Oncology Haematology Business Unit | 1975 |
| Ms. Ruth March FMEDSCI, O.B.E., Ph.D. | Senior VP of Precision Medicine - R&D Oncology | — |
Fundamentals
Valuation
Market cap$257.67B
Price-to-sales ratio4.11
Price-to-book value5.02
Price-earnings ratio24.20
Return on Equity22.00%
Return on Sales0.24%
Return on Assets0.09%
PEG ratio1.21
Earnings Per Share
Earnings Per Share$6.74
Income Statement
Average volume3,240,461
EBITDA$20.46B
1 year high (52w)$212.71
1 year low (52w)$72.90
Dividend
Ex dividend date7 Aug 2026
Dividend amount$0.00
Dividend yield1.93%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



